PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.52%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
4.09%
Positive gross profit growth while 3088.T is negative. John Neff would see a clear operational edge over the competitor.
-0.99%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1.75%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
23.00%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
22.99%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
22.99%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.00%
Slight or no buybacks while 3088.T is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.00%
Slight or no buyback while 3088.T is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
150.12%
10Y revenue/share CAGR above 1.5x 3088.T's 89.84%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
55.30%
5Y revenue/share CAGR at 50-75% of 3088.T's 78.62%. Martin Whitman would worry about a lagging mid-term growth trajectory.
35.06%
3Y revenue/share CAGR under 50% of 3088.T's 86.02%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
182.20%
Similar net income/share CAGR to 3088.T's 173.25%. Walter Schloss would see parallel tailwinds or expansions for both firms.
18.63%
Below 50% of 3088.T's 63.52%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
27.20%
Below 50% of 3088.T's 102.97%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
325.14%
10Y equity/share CAGR 1.25-1.5x 3088.T's 243.24%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
83.13%
5Y equity/share CAGR at 50-75% of 3088.T's 145.97%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
35.58%
Below 50% of 3088.T's 108.85%. Michael Burry suspects a serious short-term disadvantage in building book value.
100.00%
Below 50% of 3088.T's 300.00%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
118.18%
5Y dividend/share CAGR above 1.5x 3088.T's 71.43%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
118.18%
3Y dividend/share CAGR above 1.5x 3088.T's 71.43%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
12.35%
AR growth is negative/stable vs. 3088.T's 57.70%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
4.44%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
10.86%
Asset growth above 1.5x 3088.T's 1.98%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.19%
BV/share growth above 1.5x 3088.T's 2.01%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
218.26%
Debt growth far above 3088.T's 6.64%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
5.27%
SG&A growth well above 3088.T's 3.51%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.